R&D News | pharmaphorum

News

Gilead and Novo Nordisk collaborate for NASH trial

Gilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) combining compounds from each of their pipelines, including Novo

News

Wave slips behind in Huntington’s disease antisense race

Slower-than-expected recruitment in trials of two of Wave Life Sciences’ experimental therapies of Huntington’s disease will delay results, and lengthen the gap with a rival drug from Roche and Ion

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen announces first data centres for haematology network

Janssen has announced the first two data centres to join its HONEUR (Haematology Outcome

News

Trial sets up 2020 filing for Poxel's novel diabetes drug

French biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 diabetes, setting up a first filing in Japan next year.

News

Novartis completes spin-out of Alcon eye unit

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.

News

Gilead files Truvada follow-up Descovy for PrEP

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six m

Gilead and Novo Nordisk collaborate for NASH trial

Wave slips behind in Huntington’s disease antisense race

Janssen announces first data centres for haematology network

Trial sets up 2020 filing for Poxel's novel diabetes drug

Novartis completes spin-out of Alcon eye unit

Gilead files Truvada follow-up Descovy for PrEP

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks